Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies OXY B.H.N. — IPO Roadshow (June 2021)
27 slides from Qtrex Quantum's IPO roadshow presentation, Jun 9, 2021
Slide 1: Preventive Breakthrough Oxygenation
Preventive Breakthrough Oxygenation June 2021 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 7, 2021 Relating to Preliminary Prospectus dated June 7, 2021 Registration No. 333 - 253920 www.inspira - technologies.com
Slide 2: Free Writing Prospectus Statement
This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. The Company has filed a Registration Statement (including a pr
Slide 3: Forward-looking statements
This presentation of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans, ” “believes,” “seeks,” “estimates,” and similar e
Slide 4: Terms of the Offering
Terms of the Offering 4 Issuer Inspira Technologies Oxy B.H.N. Ltd. Offering Type Initial Public Offering Price Range $5.00 - $8.00 Units Offered Up to 2,307,692 Units plus 15%, 45 - day overallotment option Gross Proceeds $15 Million Listing/Symbol Nasdaq: IINN and IINNW Pre - Offering Shares Outst
Slide 5: About Us: Vision
Vision Redefining Artificial Respiration to impact millions of lives We are a specialty medical device company developing proprietary respiratory support technology designed to prevent the need for mechanical ventilation which is the current standard of care. About Us Proprietary - Inspira Technolog
Slide 6: Mission: new standard of care for respiratory failure
Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Early oxygen saturation elevation and stabilization are key in preventing mechanical ventilation Mission Our Mission is to become the new standard of care for deteriorating patients with respiratory failure
Slide 7: Potential to lead the Early Oxygenation Market
Potential to lead the Early Oxygenation Market With Multiple Growth Drivers Targeted Medical Device Companies 1. “Respiratory Care Devices Market by Product”. Report by “Research and Market”, June 2020. ID: 5129035 2 . Forum of International Respiratory Societies. The Global Impact of Respiratory Di
Slide 8: Redefining Artificial Respiration
Redefining Artificial Respiration We have developed a direct blood oxygenation technology called Augmented Respiration Technology In 1 minute , oxygen saturation levels can be elevated and stabilized in awake and breathing respiratory distressed patients* Comprises of a system and a disposable respi
Slide 9: Expanding $29.86 Bn Respiratory Care Market Beyond the ICU
Expanding $ 29.86 Bn Respiratory Care Market Beyond the ICU Drivers ¹ • Increase in incidence & prevalence of respiratory disease • Rise of aged population • Growing healthcare costs • ~ 20 million MV patients treated annually in ICUs ² • Increased demand for new solutions Emergency Medical Services
Slide 10: Inspira's Paradigm
Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Inspira’s Paradigm Will prevent the need for MV • Awake patient • Increased early intervention • Reduced complications Will enable availability beyond ICU ART500 is suitable for deployment in a large variety of healthcare centers and locations Drivi
Slide 11: MV has Significant Disadvantages
MV has Significant Disadvantages ¹ ˉ ³ MV requires intrusive intubation and a medically induced coma Potential Risks & Complications • Ventilator - induced lung injury (VILI) • Ventilator - associated pneumonia (VAP) • Pneumothorax & tracheomalacia • Pressure sores • Muscular atrophy • Requires wean
Slide 12: Augmented Respiration Technology
Augmented Respiration Technology Intended Patient Patients requiring respiratory support, experiencing deteriorating saturation levels (Candidates for MV) Unique Alternative Treat underlying respiratory problem while patient is awake & breathing spontaneously Patient Experience Patient awake, experi
Slide 13: ART 500 – How we expect the planned procedure to work
Awake and breathing patient lies back during the minimally invasive cannula insertion process into the jugular vein P atient can choose to sit when the ART 500 is activated Dual lumen cannula draws blood at a low flow rate 1 L/min The ART 500 oxygenates & removes CO 2 , returning the enriched blood
Slide 14: ART500 Based on Proprietary Sub-Dynamic Technology
The ART500 is Based on Inspira’s Proprietary Sub - Dynamic Technology Includes proprietary innovative features to prevent hemolysis & thrombosis Sub - Dynamic Direct Blood Oxygenation Sub - Dynamic Blood Circulation Actuated blood flow to effectively remove CO 2 and bond high concentrations of oxyge
Slide 15: ART500 Primary Sources
Dual Lumen Cannula & Adjustable Dual Lumen Component: Low impact radiography free dual lumen cannula with anti air - embolism mechanism * ART500 Primary Sources A Sub - Dynamic Pump Component: Proprietary low flow pump preventing hemolysis & thrombosis Initiation System Component: Autonomous initiat
Slide 16: ART500 Multi-Modalities
ART500 Multi - Modalities Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Support awake & breathing patients with deteriorate respiratory failure ART 500 used to provide patients early saturation elevation & stabilization • Avoid intubation, coma and MV • Avoid VALI, VIDD and VAP MV When Where IC
Slide 17: Study Results
32.60 27.50 PC 02 (P< 0.01 ) Partial Pressure of carbon dioxide ART Off* ART On* Proprietary - Inspira Technologies Oxy B.H.N. Ltd. * Average results Study Results Substantial ongoing positive changes in the blood oxygenation levels 86.40 % 95.30 % SAO 2 (P= 0.01 ) Oxygen Saturation levels ART Off*
Slide 18: Total Addressable Market for the ART
v $ 25 Bn Total Addressable Market for the ART 500 2 . Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017 20 million globally per year ² 1,250 $ per treatment $ 25 Bn Total Market Deploy ART 500 Syste
Slide 19: Market Penetration and Gaining Market Share
Market Penetration and Gaining Market Share Proprietary - Inspira Technologies Oxy B.H.N. Ltd. We have developed a flexible pricing model to drive adoption Disposable Units OPEX ART System distributed as an OPEX when bundled with 15 disposable respiratory support units Healthcare Centers, Medical Se
Slide 20: Reimbursement
Reimbursement Inspira plans to utilize existing CPT Codes using a “ New Approach ” to an existing procedure Reduced patient complications Reduced length of stay & re - admissions Reduced costs & operational expenses Reduced hospital & staff burden Proprietary - Inspira Technologies Oxy B.H.N. Ltd. c
Slide 21: Go-to-Market Strategy
Go - to - Market Strategy Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Pursuing world - wide regulatory approvals FDA/CE United States Europe Asia South America Africa, Middle East Collaborating with strategic medical centers & services Strategic partners for regional deployments ICUs, General
Slide 22: Regulatory Clearance
Regulatory Clearance A multi - step regulatory approach with multiple streams of application & revenue FDA Taking a multi - step approach to the regulatory clearance process • Submit first 510 (K) in Q 4 - 2021 relating to primary sources of the ART 500 to support Extracorporeal Life Support (ECLS)
Slide 23: Milestones Targeted for 2021-2022
Milestones Targeted for 2021 - 2022 2020 x Completed & tested prototype First 510 (k) filing First ART primary source orders, subject to regulatory clearance Collaboration with US leading medical center FDA multi - function source system filing Proprietary - Inspira Technologies Oxy B.H.N. Ltd. Q 1
Slide 24: Leadership
Leadership Urologic surgeon, inventor, entrepreneur & venture capital investor. Vast experience in leading high growth, publicly traded medical companies. Co - founded Vidamed Inc., acquired by Medtronic Inc. (NYSE: MDT). Co - founded Medinol , partnered with Boston Scientific (NYSE: BSX). Former CF
Slide 25: Scientific advisory board
Respiratory physician & specialist in respiratory disease. Professor of Respiratory Medicine at University of Notre Dame & University of WA. Chairman of Research at UND, Director of the WA Lung Transplant Program, Sub - training at Freeman Hospital in Newcastle upon Tyne, Stanford University, Palo A
Slide 26: Investment Highlights
Investment Highlights • Innovative and cost - effective respiratory technology • Early saturation elevation to prevent the use of MV • Patients treated while awake, responsive & breathing spontaneously • Raises saturation levels in 1 minute • Reduces hospitalization stay and treatment costs • Total
Slide 27: Thank You
Thank You Joe Hayon Co - Founder, President & CFO E - mail : joe@inspirao 2 .com www.inspira - technologies.com
Inspira Technologies OXY B.H.N. — IPO Roadshow (June 2021) on 6ix